ファーマコビジランスの世界市場レポート 2025年

ファーマコビジランス市場規模は、今後数年で急成長が見込まれます。2029年には158億3,000万米ドルに成長し、CAGRは12.9%となります。予測期間の成長は、ヘルスケア支出の増加、政府支援の増加、人口の高齢化に起因しています。予測期間における主な動向としては、投資の増加、人工知能の利用、革新的なプラットフォームの利用、革新的なクラウドベースのシステムの利用、戦略的M&Aなどが挙げられます。

研究開発活動の活発化がファーマコビジランス市場を促進すると予測されます。研究開発に投資することで、製薬企業は安全性プロファイルを強化した革新的な新薬を生み出すことができます。医薬品開発プロセスにおける厳格な前臨床試験と臨床試験により、潜在的な安全性問題を早期に特定することができ、効果的なリスク軽減戦略の実施が可能になります。さらに、研究開発努力により、有害事象のモニタリング、データ解析、シグナル検出の技術が進歩し、市販後段階での副作用の早期発見が容易になります。例えば、2024年2月、英国の機関であるLlywodraeth Cymruウェールズ政府は、ウェールズが2022年に10億ポンド（12億5,000万米ドル）を研究開発事業費（BERD）に投資し、この分野での英国総支出の1.9％を占めると報告しました。このように、研究開発活動の成長がファーマコビジランス市場を牽引しています。

ヘルスケア支出の増加は、予測期間中のファーマコビジランス市場の成長を促進すると予想されます。追加資金により、ヘルスケアシステムは、副作用を効果的に特定し評価するための先進技術、データ分析、専門家チームに投資することができます。さらに、ヘルスケア支出の拡大は、医療専門家に対するファーマコビジランスの実践に関するより良いトレーニングと教育を促進し、潜在的な薬剤関連問題のタイムリーな報告と分析を保証します。例えば、2024年6月、英国を拠点とする非営利団体The King's Fundは、英国が2022年にGDPの11.3%をヘルスケアに充て、類似国の平均をわずかに上回ったと報告しました。これは、COVID-19パンデミック以前のGDPの9.9％から増加したことになります。この支出の増加は、パンデミックに対応してヘルスケア・サービスが重視されるようになったことを強調するもので、資金調達の優先順位が大きく変わったことを示しています。したがって、ヘルスケア支出の増加は、今後のファーマコビジランス市場の成長を支えると思われます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ファーマコビジランス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のファーマコビジランス市場：成長率分析
• 世界のファーマコビジランス市場の実績：規模と成長, 2019-2024
• 世界のファーマコビジランス市場の予測：規模と成長, 2024-2029, 2034F
• 世界ファーマコビジランス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のファーマコビジランス市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自発的な報告
• ADR報告の強化
• 対象を絞った自発的な報告
• コホートイベントモニタリング
• EHRマイニング
• 世界のファーマコビジランス市場サービスプロバイダー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 社内
• 契約アウトソーシング
• 世界のファーマコビジランス市場プロセスフロー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ケースデータ管理
• 信号検出
• リスク管理システム
• 世界のファーマコビジランス市場臨床試験の段階別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前臨床
• フェーズI
• フェーズII
• フェーズIII
• フェーズIV
• 世界のファーマコビジランス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 製薬会社
• その他のエンドユーザー
• 世界のファーマコビジランス市場、自発的報告のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 個別症例安全性報告書（ICSR）
• 自主報告システム
• ヘルスケア専門家による症例報告
• 世界のファーマコビジランス市場、強化されたADR報告のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アクティブ監視プログラム
• 臨床試験における強化されたモニタリング
• リスク最小化戦略
• 世界のファーマコビジランス市場、対象を絞った自発的報告のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特定の薬物クラスの報告
• 状態別レポート
• 集中監視プログラム
• 世界のファーマコビジランス市場、コホートイベントモニタリングのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前向きコホート研究
• 遡及的コホート研究
• 縦断的研究
• 世界のファーマコビジランス市場EHRマイニングのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 電子健康記録からのデータ抽出
• EHR分析によるシグナル検出
• EHRデータとファーマコビジランスシステムの統合

第7章 地域別・国別分析

• 世界のファーマコビジランス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のファーマコビジランス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ファーマコビジランス市場：競合情勢
• ファーマコビジランス市場：企業プロファイル
  • IQVIA Overview, Products and Services, Strategy and Financial Analysis
  • Cognizant Overview, Products and Services, Strategy and Financial Analysis
  • ICON Plc Overview, Products and Services, Strategy and Financial Analysis
  • Accenture plc Overview, Products and Services, Strategy and Financial Analysis
  • PAREXEL International Corporation. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• United BioSource LLC
• ArisGlobal
• Quanticate
• Wipro Limited
• Linical Americas
• Novotech CRO
• Wuxi Apptec
• Simcere Pharmaceutical Group
• Lee's Pharmaceutical Holdings
• Luye Pharma Group
• EXTEDO
• Arriello
• PrimeVigilance
• Axios International
• C3i Solutions

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ファーマコビジランス市場2029：新たな機会を提供する国
• ファーマコビジランス市場2029：新たな機会を提供するセグメント
• ファーマコビジランス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pharmacovigilance encompasses the science and practices dedicated to identifying, evaluating, understanding, and mitigating side effects and other medical/vaccination-related issues. Its purpose is to assess whether the benefits of a drug outweigh its risks, and this scrutiny persists even after drug approval.

The primary types of pharmacovigilance include spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining. Spontaneous reporting relies on individuals' voluntary reporting of suspected adverse drug reactions to local or national pharmacovigilance centers, representing a passive approach. Process flows involve case data management, signal detection, and risk management systems. Service providers can be in-house or contracted for outsourcing, covering various clinical trial phases such as preclinical, phase I, phase II, phase III, and phase IV. These services cater to different end-users, including hospitals, pharmaceutical companies, and others.

The pharmacovigilance market research report is one of a series of new reports from The Business Research Company that provides pharmacovigilance market statistics, including pharmacovigilance industry global market size, regional shares, competitors with a pharmacovigilance market share, detailed pharmacovigilance market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmacovigilance industry. This pharmacovigilance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmacovigilance market size has grown rapidly in recent years. It will grow from $8.58 billion in 2024 to $9.73 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to the increasing incidence of adverse drug reactions (ADRs), the increasing research and development (R&D) activities, the growing drug development rates, the increasing focus on personalized medicine, and the rising prevalence of chronic diseases.

The pharmacovigilance market size is expected to see rapid growth in the next few years. It will grow to $15.83 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to the rising healthcare expenditure, the increasing government support and the aging population. Major trends in the forecast period include increasing investments, use of artificial intelligence, use of innovative platforms, use of innovative cloud-based systems, and strategic mergers and acquisitions.

The rise in research and development activities is expected to propel the pharmacovigilance market. By investing in R&D, pharmaceutical companies can create new and innovative drugs with enhanced safety profiles. The rigorous preclinical and clinical testing during the drug development process allows for the early identification of potential safety issues, enabling the implementation of effective risk mitigation strategies. Furthermore, R&D efforts advance technologies for monitoring adverse events, data analysis, and signal detection, which facilitate the early identification of adverse drug reactions during the post-marketing phase. For example, in February 2024, the Llywodraeth Cymru Welsh Government, a UK-based agency, reported that Wales invested £1.0 billion ($1.25 billion) in Business Expenditure on Research and Development (BERD) in 2022, representing 1.9% of the total UK expenditure in this area. Thus, the growth in research and development activities is driving the pharmacovigilance market.

The increase in healthcare expenditure is expected to drive the growth of the pharmacovigilance market during the forecast period. With additional funding, healthcare systems can invest in advanced technologies, data analytics, and dedicated expert teams to effectively identify and assess adverse drug reactions. Moreover, greater healthcare spending facilitates better training and education for healthcare professionals on pharmacovigilance practices, ensuring timely reporting and analysis of potential drug-related issues. For example, in June 2024, The King's Fund, a UK-based non-profit organization, reported that the UK allocated 11.3% of its GDP to healthcare in 2022, slightly above the average for similar countries. This represents an increase from the pre-COVID-19 pandemic level of 9.9% of GDP dedicated to health services. This rise in expenditure underscores a growing emphasis on healthcare services in response to the pandemic, indicating a significant shift in funding priorities. Therefore, the increasing healthcare expenditure will support the growth of the pharmacovigilance market in the future.

Companies in the pharmacovigilance market are increasingly leveraging artificial intelligence (AI) to enhance efficiency. AI technology can significantly improve the accuracy and efficiency of pharmacovigilance activities, ultimately resulting in better patient outcomes. By incorporating AI, pharmaceutical companies can streamline processes, enhance data management, and expedite drug discovery, all while reducing costs and increasing safety. For example, in August 2024, the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, unveiled by the Minister of Health & Family Welfare and the Minister of Chemicals and Fertilizers. This pharmacovigilance software aids in the collection and analysis of adverse events related to medicines and medical devices, simplifying the reporting process for both consumers and healthcare professionals. This initiative considerably bolsters India's pharmacovigilance infrastructure by ensuring a more thorough capture of safety data and enhancing drug safety monitoring. The ADRMS aims to improve the efficiency of drug safety oversight and compliance with regulatory standards, positioning India as a leader in the global pharmaceutical industry.

Pharmacovigilance providers are making substantial investments to expand their product portfolios and geographic presence. In September 2022, the PharmaLex Group opened a new branch in Beijing, China, offering comprehensive pharmacovigilance, regulatory affairs, development advice, and quality management services to global companies entering the Chinese market. The PharmaLex Group's expansion aims to provide enhanced support and value across the product lifecycle.

In January 2023, AmerisourceBergen acquired Pharma Lex to augment its existing service offering and provide pharmaceutical and biotech companies with comprehensive support for pharmacovigilance systems and operations, including benefit-risk management services. These strategic investments contribute to the growth and expansion of the pharmacovigilance market.

Major companies operating in the pharmacovigilance market include IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation., United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, Wuxi Apptec, Simcere Pharmaceutical Group, Lee's Pharmaceutical Holdings, Luye Pharma Group, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Alcon, Secure AI Labs, OmniSol dot Tech, Canna Call Company, Veripad, Prevnos Inc., Lifescient, Inc, BeiGene, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., MSD, Novasyte, Fortrea Holdings Inc, Syneos Health Clinical, Zoetis Inc., Telerx Marketing Inc., Gilead Sciences, Inc., Elanco, Abbott Laboratories, Spimaco, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the pharmacovigilance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharmacovigilance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The pharmacovigilance market includes revenues earned by collecting, analyzing, monitoring, and preventing adverse effects in drugs and therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmacovigilance Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmacovigilance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharmacovigilance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmacovigilance market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining
• 2) By Service Provider: In-House, Contract Outsourcing
• 3) By Process Flow: Case Data Management, Signal Detection, Risk Management System
• 4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV
• 5) By End User: Hospitals, Pharmaceutical Companies, Other End Users
• Subsegments:
• 1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs); Voluntary Reporting Systems; Case Reports From Healthcare Professionals
• 2) By Intensified ADR Reporting: Active Surveillance Programs; Enhanced Monitoring In Clinical Trials; Risk Minimization Strategies
• 3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes; Condition-Specific Reporting; Focused Surveillance Programs
• 4) By Cohort Event Monitoring: Prospective Cohort Studies; Retrospective Cohort Studies; Longitudinal Studies
• 5) By EHR Mining: Data Extraction From Electronic Health Records; Signal Detection Through EHR Analysis; Integration Of EHR Data With Pharmacovigilance Systems
• Companies Mentioned: IQVIA; Cognizant; ICON Plc; Accenture plc; PAREXEL International Corporation.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pharmacovigilance Market Characteristics

3. Pharmacovigilance Market Trends And Strategies

4. Pharmacovigilance Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pharmacovigilance Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pharmacovigilance PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pharmacovigilance Market Growth Rate Analysis
• 5.4. Global Pharmacovigilance Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pharmacovigilance Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pharmacovigilance Total Addressable Market (TAM)

6. Pharmacovigilance Market Segmentation

• 6.1. Global Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining
• 6.2. Global Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• In-House
• Contract Outsourcing
• 6.3. Global Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Case Data Management
• Signal Detection
• Risk Management System
• 6.4. Global Pharmacovigilance Market, Segmentation By Clinical Trial Phases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical
• Phase I
• Phase II
• Phase III
• Phase IV
• 6.5. Global Pharmacovigilance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmaceutical Companies
• Other End Users
• 6.6. Global Pharmacovigilance Market, Sub-Segmentation Of Spontaneous Reporting, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Individual Case Safety Reports (ICSRs)
• Voluntary Reporting Systems
• Case Reports From Healthcare Professionals
• 6.7. Global Pharmacovigilance Market, Sub-Segmentation Of Intensified ADR Reporting, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Active Surveillance Programs
• Enhanced Monitoring In Clinical Trials
• Risk Minimization Strategies
• 6.8. Global Pharmacovigilance Market, Sub-Segmentation Of Targeted Spontaneous Reporting, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reporting For Specific Drug Classes
• Condition-Specific Reporting
• Focused Surveillance Programs
• 6.9. Global Pharmacovigilance Market, Sub-Segmentation Of Cohort Event Monitoring, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prospective Cohort Studies
• Retrospective Cohort Studies
• Longitudinal Studies
• 6.10. Global Pharmacovigilance Market, Sub-Segmentation Of EHR Mining, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Data Extraction From Electronic Health Records
• Signal Detection Through EHR Analysis
• Integration Of EHR Data With Pharmacovigilance Systems

7. Pharmacovigilance Market Regional And Country Analysis

• 7.1. Global Pharmacovigilance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pharmacovigilance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pharmacovigilance Market

• 8.1. Asia-Pacific Pharmacovigilance Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pharmacovigilance Market

• 9.1. China Pharmacovigilance Market Overview
• 9.2. China Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pharmacovigilance Market

• 10.1. India Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pharmacovigilance Market

• 11.1. Japan Pharmacovigilance Market Overview
• 11.2. Japan Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pharmacovigilance Market

• 12.1. Australia Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pharmacovigilance Market

• 13.1. Indonesia Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pharmacovigilance Market

• 14.1. South Korea Pharmacovigilance Market Overview
• 14.2. South Korea Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pharmacovigilance Market

• 15.1. Western Europe Pharmacovigilance Market Overview
• 15.2. Western Europe Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pharmacovigilance Market

• 16.1. UK Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pharmacovigilance Market

• 17.1. Germany Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pharmacovigilance Market

• 18.1. France Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pharmacovigilance Market

• 19.1. Italy Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pharmacovigilance Market

• 20.1. Spain Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pharmacovigilance Market

• 21.1. Eastern Europe Pharmacovigilance Market Overview
• 21.2. Eastern Europe Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pharmacovigilance Market

• 22.1. Russia Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pharmacovigilance Market

• 23.1. North America Pharmacovigilance Market Overview
• 23.2. North America Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pharmacovigilance Market

• 24.1. USA Pharmacovigilance Market Overview
• 24.2. USA Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pharmacovigilance Market

• 25.1. Canada Pharmacovigilance Market Overview
• 25.2. Canada Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pharmacovigilance Market

• 26.1. South America Pharmacovigilance Market Overview
• 26.2. South America Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pharmacovigilance Market

• 27.1. Brazil Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pharmacovigilance Market

• 28.1. Middle East Pharmacovigilance Market Overview
• 28.2. Middle East Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pharmacovigilance Market

• 29.1. Africa Pharmacovigilance Market Overview
• 29.2. Africa Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pharmacovigilance Market Competitive Landscape And Company Profiles

• 30.1. Pharmacovigilance Market Competitive Landscape
• 30.2. Pharmacovigilance Market Company Profiles
  • 30.2.1. IQVIA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Cognizant Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. ICON Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Accenture plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. PAREXEL International Corporation. Overview, Products and Services, Strategy and Financial Analysis

31. Pharmacovigilance Market Other Major And Innovative Companies

• 31.1. United BioSource LLC
• 31.2. ArisGlobal
• 31.3. Quanticate
• 31.4. Wipro Limited
• 31.5. Linical Americas
• 31.6. Novotech CRO
• 31.7. Wuxi Apptec
• 31.8. Simcere Pharmaceutical Group
• 31.9. Lee's Pharmaceutical Holdings
• 31.10. Luye Pharma Group
• 31.11. EXTEDO
• 31.12. Arriello
• 31.13. PrimeVigilance
• 31.14. Axios International
• 31.15. C3i Solutions

32. Global Pharmacovigilance Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmacovigilance Market

34. Recent Developments In The Pharmacovigilance Market

35. Pharmacovigilance Market High Potential Countries, Segments and Strategies

• 35.1 Pharmacovigilance Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pharmacovigilance Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pharmacovigilance Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer